刘翠玉, 历素萍, 潘宝山, 邢辉, 梁博慧, 荣天畅, 张慧. 2017-2020年黑龙江省佳木斯市肺结核患者耐药情况分析[J]. 疾病监测, 2021, 36(10): 1052-1056. DOI: 10.3784/jbjc.202105130269
引用本文: 刘翠玉, 历素萍, 潘宝山, 邢辉, 梁博慧, 荣天畅, 张慧. 2017-2020年黑龙江省佳木斯市肺结核患者耐药情况分析[J]. 疾病监测, 2021, 36(10): 1052-1056. DOI: 10.3784/jbjc.202105130269
Liu Cuiyu, Li Suping, Pan Baoshan, Xing Hui, Liang Bohui, Rong Tianchang, Zhang Hui. Drug resistance in pulmonary tuberculosis patients in Jiamusi, Heilongjiang, 2017–2020[J]. Disease Surveillance, 2021, 36(10): 1052-1056. DOI: 10.3784/jbjc.202105130269
Citation: Liu Cuiyu, Li Suping, Pan Baoshan, Xing Hui, Liang Bohui, Rong Tianchang, Zhang Hui. Drug resistance in pulmonary tuberculosis patients in Jiamusi, Heilongjiang, 2017–2020[J]. Disease Surveillance, 2021, 36(10): 1052-1056. DOI: 10.3784/jbjc.202105130269

2017-2020年黑龙江省佳木斯市肺结核患者耐药情况分析

Drug resistance in pulmonary tuberculosis patients in Jiamusi, Heilongjiang, 2017–2020

  • 摘要:
      目的   了解黑龙江省佳木斯市肺结核患者的耐药情况,为结核病疫情防控提供可靠的参考依据。
      方法   收集2017 — 2020年黑龙江省佳木斯市结核病参比实验室接收的575例分枝杆菌培养阳性患者菌株进行菌种鉴定,采用固体比例法进行药物敏感度测试,分析异烟肼、利福平、乙胺丁醇、链霉素、氧氟沙星、卡那霉素的药敏试验结果。
      结果   总耐药率为35.29%(198/561),初治患者总耐药率为32.35%(143/442),复治患者总耐药率为46.22%(55/119),两者间差异有统计学意义(χ2=7.893,P=0.005);总耐多药率为10.16%(57/561),初治患者耐多药率为7.92%(35/442),复治患者耐多药率为18.49%(22/119),两者间差异有统计学意义(χ2=11.473,P=0.01)。 结核分枝杆菌菌株耐药率顺位分别是链霉素(22.82%,128/561)、异烟肼(19.25%,108/561)、利福平(15.69%,88/561)、氧氟沙星(6.77%,38/561)、乙胺丁醇(6.6%,37/561)、卡那霉素(2.14%,12/561)。
      结论   2017 — 2020年佳木斯市肺结核病耐药情况较严重,特别是利福平耐药患者的比例较高,应尽早发现耐药结核病患者并进行针对性规范化治疗管理,避免耐药结核病的传播。

     

    Abstract:
      Objective  To understand the prevalence of drug resistance in pulmonary tuberculosis (TB) patients in Jiamusi, Heilongjiang province, and provide reliable references for the prevention and control of TB.
      Methods  Mycobacterium tuberculosis strains isolated from 575 TB cases collected by Jiamusi Tuberculosis Reference Laboratory from 2017 to 2020 were included in the study. Proportion method was used for the drug susceptibility test of the strains to isoniazid, rifampicin, ethambutol, streptomycin, ofloxacin and kanamycin.
      Results  The overall drug resistance rate was 35.29% (198/561). The drug resistance rate of the strains from the previously untreated patients was 32.35% (143/442), and the drug resistance rate of the strains from the retreated patients was 46.22% (55/119). There was significant difference between the two groups in drug resistance rate ( χ2=7.893, P=0.005). The overall multi-drug resistance rate was 10.16% (57/561). The multi-drug resistance rate of the strains from the previously untreated patients was 7.92% (35/442), and the multi-drug resistance rate of the strains from the retreated patients was 18.49% (22/119). There was significant difference between the two groups in multi-drug resistance rate ( χ2=11.473, P=0.01).The drug resistance rates of the M. tuberculosis strains to 6 anti TB drugs were 22.82% (128/561) to streptomycin , 19.25% (108/561) to isoniazid, 15.69% (88/561) to rifampicin , 6.77% (38/561) to ofloxacin, 6.6% (37/561) to ethambutol and 2.14% (12/561) to kanamycin.
      Conclusion  The drug resistance in pulmonary TB patients in Jiamusi was relatively serious, and the proportion of rifampicin resistant TB patients was relatively high. It is suggested that early detection and standardized treatment of TB patients with drug resistance should be strengthened to control the spread of drug resistant TB.

     

/

返回文章
返回